+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
NEPHROPLUS

Nephrocare Health Services Share Price

₹747.25 +13.8 (1.88%)

10 Sep, 2026 3:53 PM (IST)

Nephrocare Health Services live price: ₹747.25. It opened at ₹733 vs previous close ₹733; intraday high/low: ₹751/₹731. The 50 DMA stands at ₹687.20.

Nephrocare Health Services Performance

  • Today's Low
  • ₹731
  • Today's High
  • ₹751
  • 52 Week Low
  • ₹446
  • 52 Week High
  • ₹770
  • Open Price₹733
  • Previous Close₹733
  • Volume218,705
  • 50 DMA₹687.20
  • 100 DMA₹656.20
  • 200 DMA-

Nephrocare Health Services Chart

Investment Returns

  • Over 1 Month + 7.1%
  • Over 3 Month + 3.33%
  • Over 6 Month + 27.2%
  • Over 1 Year + 62.45%

Smart Investing Starts Here Start SIP with Nephrocare Health Services for Steady Growth!

Invest Now

Nephrocare Health Services Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 88.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 7,498
  • P/B Ratio
  • 6.5
  • Average True Range
  • 26.1
  • EPS
  • 8.5
  • Dividend Yield
  • 0
  • MACD Signal
  • 12.7
  • RSI
  • 65.01
  • MFI
  • 83.89

Latest Stock News Updates

Nephrocare Health Services Ltd - 544647 - Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026.

We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.

Nephrocare Health Services Ltd - 544647 - Announcement under Regulation 30 (LODR)-Acquisition

Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP, an overseas subsidiary of the Company has entered into a Share Purchase Agreement for acquisition of 100% participatory interest in Dialysis Center Almaty LLP in Kazakhstan as per the disclosure annexed herewith.

Nephrocare Health Services Ltd - 544647 - Disclosure Under Regulation 30 Of SEBI Listing Regulations

Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that the Company has received Tax demand pursuant to Tax Audit as per the annexed disclosure.

Nephrocare Health Services Financials

Nephrocare Health Services Technicals

EMA & SMA

Current Price
₹747.25
+ 13.8 (1.88%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 14
  • 20 Day
  • ₹705.60
  • 50 Day
  • ₹687.20
  • 100 Day
  • ₹656.20
  • 200 Day
  • -

Resistance and Support

743.15 Pivot Speed
  • R3 775.40
  • R2 763.20
  • R1 755.20
  • S1 735.20
  • S2 723.00
  • S3 715.00

Nephrocare Health Services Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-11 Quarterly Results o approve the financial results for the quarter ended June 30, 2026.
2026-05-19 Audited Results
2026-02-10 Quarterly Results

Nephrocare Health Services Shareholding Pattern

63.85%
18.3%
8.78%
5.85%
3.2%

About Nephrocare Health Services

Nephrocare Health Services has been set up for the purpose of providing dialysis healthcare services through a chain of kidney care clinics. View More
  • NSE Symbol
  • NEPHROPLUS
  • BSE Symbol
  • 544647
  • ISIN
  • INE428V01029

Similar Stocks to Nephrocare Health Services

Nephrocare Health Services FAQs

Nephrocare Health Services share price is ₹747 As on 11 September, 2026 | 08:29

The Market Cap of Nephrocare Health Services is ₹7498 Cr As on 11 September, 2026 | 08:29

The P/E ratio of Nephrocare Health Services is 88.1 As on 11 September, 2026 | 08:29

The PB ratio of Nephrocare Health Services is 6.5 As on 11 September, 2026 | 08:29

The 52 week High & Low of Nephrocare Health Services is ₹769.8/₹446 respectively As on 11 September, 2026 | 08:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23